Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications.
暂无分享,去创建一个
[1] M. Velasco,et al. Effect of Prazosin on Blood Lipids and on Thyroid Function in Hypertensive Patients , 1982, Journal of cardiovascular pharmacology.
[2] G. Stokes,et al. Influence of dosage and dietary sodium on the first-dose effects of prazosin. , 1977, British medical journal.
[3] E. Braunwald,et al. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. , 1981, The New England journal of medicine.
[4] N. Hollenberg,et al. Relation of the Renin‐Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure , 1981, Circulation.
[5] E. Braunwald,et al. Long-term therapy of heart failure with prazosin: a randomized double blind trial. , 1980, The American journal of cardiology.
[6] C. Desch,et al. Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose. , 1981, Annals of internal medicine.
[7] E. Braunwald,et al. Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure. , 1981, The American journal of medicine.
[8] P. Fauchald,et al. Treatment of hypertension with prazosin. An open study in general practice. , 2009, Acta medica Scandinavica. Supplementum.
[9] G. Hirst,et al. Evidence for two populations of excitatory receptors for noradrenaline on arteriolar smooth muscle , 1980, Nature.
[10] T. Dillon,et al. Vasodilator therapy for congestive heart failure. , 1980, The Journal of pediatrics.
[11] J. Longhurst,et al. Peripheral circulatory control mechanisms in congestive heart failure. , 1973, The American journal of cardiology.
[12] L. Benet,et al. Attenuation of prazosin effect on cardiac output in chronic heart failure. , 1979, Annals of internal medicine.
[13] J. H. Acosta. Hypertension in chronic renal disease. , 1982, Kidney international.
[14] J. Hampton,et al. DANGER OF WITHDRAWAL OF VASODILATOR THERAPY IN PATIENTS WITH CHRONIC HEART-FAILURE , 1980, The Lancet.
[15] R. Gorlin,et al. Determinants of Drug Response in Severe Chronic Heart Failure. 1. Activation of Vasoconstrictor Forces During Vasodilator Therapy , 1981, Circulation.
[16] E. Braunwald,et al. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. , 1962, The New England journal of medicine.
[17] R. Smith,et al. Acute tolerance to prazosin in conscious hypertensive rats: involvement of the renin-angiotensin system. , 1981, The Journal of pharmacology and experimental therapeutics.
[18] A. DeMaria,et al. Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. , 1981, American heart journal.
[19] J. A. Thomas,et al. Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.
[20] N. Hollenberg,et al. When is loss of responsiveness to a vasodilator agent in the patient with congestive heart failure due to tachyphylaxis? , 1980, American heart journal.
[21] M. Blaufox,et al. Physiologic Evaluation of a New Antihypertensive Agent: Prazosin HCl , 1977, Circulation.
[22] R. Lefkowitz,et al. Alpha-adrenergic receptor subtypes. , 1980, The New England journal of medicine.
[23] K. Murata,et al. Effect of Prazosin on Serum Lipids , 1982, Journal of cardiovascular pharmacology.
[24] J. Cohn,et al. Neurohumoral control mechanisms in congestive heart failure. , 1981, American heart journal.
[25] E. Speers,et al. Experience with prazosin in the treatment of patients with severe hypertension. , 1976, The Medical journal of Australia.
[26] T. Levine,et al. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. , 1981, The American journal of cardiology.
[27] R. Waldo. Prazosin relieves Raynaud's vasospasm. , 1979, JAMA.
[28] C. Rosendorff. Prazosin: severe side effects are dose-dependent. , 1976, British medical journal.
[29] W. Pettinger,et al. A functional basis for classification of α-adrenergic receptors , 1977 .
[30] R. Miller,et al. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. , 1977, The New England journal of medicine.
[31] L. Johnson,et al. Improved exercise ejection fraction with long-term prazosin therapy in patients with heart failure. , 1980, The American journal of medicine.
[32] P. Mchenry,et al. Acute and chronic haemodynamic effects of prazosin in left ventricular failure. , 1981, British heart journal.
[33] J. Cohn,et al. Effect of prazosin on renal function in congestive heart failure , 1980, Clinical pharmacology and therapeutics.
[34] D. Mason,et al. Therapeutic application of prazosin in chronic refractory congestive heart failure. Tolerance and "tachyphylaxis" in perspective. , 1981, The American journal of medicine.
[35] S. Z. Langer,et al. Recent Developments In Noradrenergic Neurotransmission and its Relevance to the Mechanism of Action of Certain Antihypertensive Agents , 1980, Hypertension.
[36] J. Wallace,et al. Prazosin in the diagnosis and treatment of pheochromocytoma. , 1978, JAMA.
[37] W. Pettinger,et al. Effects of Prazosin and Phentolamine on Arterial Pressure, Heart Rate, and Renin Activity: Evidence in the Conscious Rat for the Functional Significance of the Presynaptic α-Receptor , 1979, Journal of cardiovascular pharmacology.
[38] M. Cohen,et al. In vitro relaxation of arteries and veins by prazosin: alpha-adrenergic blockade with no direct vasodilation. , 1979, Blood & Vessel.
[39] C. Desch,et al. Development of pharmacodynamic tolerance to prozosin in congestive heart failure. , 1979, The American journal of cardiology.
[40] R. Gorlin,et al. Hemodynamic and Clinical Tachyphylaxisc to Prazosin-Mediated Afterload Reductionin Severe Chronic Congestive Heart Failure , 1979, Circulation.
[41] W. Kirkendall,et al. Prazosin and clonidine for moderately severe hypertension. , 1978, JAMA.
[42] D. S. Cobaugh. Prazosin treatment of ergotamine-induced peripheral ischemia. , 1980, JAMA.
[43] R. Alexander,et al. Regulation of the Postsynaptic α‐Adrenergic Receptor in Rat Mesenteric Artery: Effects of Chemical Sympathectomy and Epinephrine Treatment 1981 , 1981, Circulation research.
[44] R. Gorlin,et al. Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure. , 1982, The New England journal of medicine.
[45] J. Mahony,et al. LONG‐TERM USE OF PRAZOSIN IN COMBINATION OR ALONE FOR TREATING HYPERTENSION , 1977, The Medical journal of Australia.
[46] E. Braunwald,et al. Improved right ventricular function and reduced pulmonary vascular resistance during prazosin therapy of congestive heart failure. , 1981, The American journal of medicine.
[47] P. Bolli,et al. Prazosin in normal subjects: plasma levels, blood pressure and heart rate. , 1976, British journal of clinical pharmacology.
[48] D. Harrison,et al. Beneficial hemodynamic response to chronic prazosin therapy in congestive heart failure. , 1981, American heart journal.